Received Apr 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | 3E99M | SC / LA |
of suspect vaccine subcutaneously instead of intramuscularly; This non-serious case was reported by a nurse via call center representative and described the occurrence of intramuscular formulation administered by other route in a male patient who received Men ACWY-CRM NVS (Menveo) (batch number 3E99M, expiry date 31-DEC-2025) for prophylaxis. On an unknown date, the patient received the 1st dose of Menveo (subcutaneous, left deltoid) .5 ml. On an unknown date, an unknown time after receiving Menveo, the patient experienced intramuscular formulation administered by other route (Verbatim: of suspect vaccine subcutaneously instead of intramuscularly). The outcome of the intramuscular formulation administered by other route was not applicable. Additional Information: GSK Receipt Date: 27-MAR-2025 The reporter was the healthcare professional calling from a facility to get further guidance from MI. The reporter stated that a minor child received first dose of suspect vaccine subcutaneously instead of intramuscularly in his left lower deltoid which led to intramuscular formulation administered by other route. The reporter did not provide the date that the vaccine was given.